2025 Drug Approvals: Ozempic to Yeztugo, Reshaping Treatment

• Ozempic (semaglutide) gained expanded approval in 2025 to reduce chronic kidney disease progression and cardiovascular death risk in type 2 diabetes patients.
• Journavx (suzetrigine) was approved as the first new class of non-opioid acute pain medicine in over two decades, offering relief without dependence risks.
• Neffy, an epinephrine nasal spray, was approved for pediatric allergy care, providing a needle-free alternative for anaphylaxis treatment.
• Yeztugo (lenacapavir), a twice-yearly injectable, reshaped HIV prevention (PrEP) with near-total transmission reduction compared to daily pills.
• Dupixent became the first targeted therapy for bullous pemphigoid, and Blujepa was approved as a new oral treatment for drug-resistant gonorrhea.

Why It Matters: New 2025 drug approvals offer revolutionary treatments for major health challenges.